GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (OTCPK:CSPHF) » Definitions » EV-to-EBITDA

CStone Pharmaceuticals (CStone Pharmaceuticals) EV-to-EBITDA : -0.81 (As of May. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CStone Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CStone Pharmaceuticals's enterprise value is $84.41 Mil. CStone Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-103.67 Mil. Therefore, CStone Pharmaceuticals's EV-to-EBITDA for today is -0.81.

The historical rank and industry rank for CStone Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

CSPHF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.3   Med: -2.46   Max: -0.82
Current: -0.82

During the past 8 years, the highest EV-to-EBITDA of CStone Pharmaceuticals was -0.82. The lowest was -10.30. And the median was -2.46.

CSPHF's EV-to-EBITDA is ranked worse than
100% of 465 companies
in the Biotechnology industry
Industry Median: 9.34 vs CSPHF: -0.82

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), CStone Pharmaceuticals's stock price is $0.12. CStone Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.090. Therefore, CStone Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


CStone Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for CStone Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals EV-to-EBITDA Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -2.78 -5.56 -3.41 -4.96 -6.67

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.41 - -4.96 - -6.67

Competitive Comparison of CStone Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, CStone Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CStone Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CStone Pharmaceuticals's EV-to-EBITDA falls into.



CStone Pharmaceuticals EV-to-EBITDA Calculation

CStone Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=84.407/-103.668
=-0.81

CStone Pharmaceuticals's current Enterprise Value is $84.41 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CStone Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-103.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CStone Pharmaceuticals  (OTCPK:CSPHF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CStone Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.12/-0.090
=At Loss

CStone Pharmaceuticals's share price for today is $0.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CStone Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.090.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


CStone Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CStone Pharmaceuticals (CStone Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (CStone Pharmaceuticals) Headlines

From GuruFocus